DrugPatentWatch Database Preview

Details for Patent: 8,372,431

Which drugs does patent 8,372,431 protect, and when does it expire?

Patent 8,372,431 protects APTIOM and is included in one NDA.

This patent has twenty-four patent family members in twenty-three countries.

Summary for Patent: 8,372,431

Title:	Pharmaceutical composition comprising licarbazepine acetate
Abstract:	A pharmaceutical composition comprising licarbazepine acetate, especially eslicarbazepine acetate, in combination with suitable excipients, in particular a binder, and a disintegrant. Also disclosed is a granulation process, especially a wet granulation process, for making the pharmaceutical composition.
Inventor(s):	Cardoso de Vasconcelos; Teofilo (S. Mamede do Coronado, PT), dos Santos Lima; Ricardo Jorge (S. Mamede do Coronado, PT), Cerdeira de Campos Costa; Rui (S. Mamede do Coronado, PT)
Assignee:	BIAL-Portela & C.A., S.A. (S. Mamede do Coronado, PT)
Application Number:	12/257,240
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,372,431
Patent Claim Types: see list of patent claims	Composition; Formulation; Device; Dosage form;

Drugs Protected by US Patent 8,372,431

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Sunovion Pharms Inc	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-001	Nov 8, 2013		RX	Yes	No	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Sunovion Pharms Inc	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-002	Nov 8, 2013		RX	Yes	No	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Sunovion Pharms Inc	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-003	Nov 8, 2013		RX	Yes	No	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Sunovion Pharms Inc	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-004	Nov 8, 2013		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 8,372,431

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
9,566,244	Pharmaceutical composition comprising licarbazepine acetate	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 8,372,431

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	069031	➤ Sign Up
Australia	2008317584	➤ Sign Up
Canada	2703313	➤ Sign Up
China	101848698	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 8,372,431

For more information try a trial or see the plans and pricing